Get the Stockscreener App
0.279
63.92%
0.1088
Aptose Biosciences Inc stock is traded at $0.279, with a volume of 304.66M.
It is up +63.92% in the last 24 hours and up +2.16% over the past month.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
See More
Previous Close:
$0.1702
Open:
$0.27
24h Volume:
304.66M
Relative Volume:
54.79
Market Cap:
$16.61M
Revenue:
-
Net Income/Loss:
$-51.21M
P/E Ratio:
-0.0357
EPS:
-7.82
Net Cash Flow:
$-44.62M
1W Performance:
+44.56%
1M Performance:
+2.16%
6M Performance:
-65.11%
1Y Performance:
-88.03%
1-Day Range:
$0.2106
$0.3895
1-Week Range:
$0.17
$0.3895
52-Week Range:
$0.13
$2.68
Aptose Biosciences Inc Stock (APTO) Company Profile
Name
Aptose Biosciences Inc
Sector
Industry
Phone
310-849-8060
Address
66 WELLINGTON STREET WEST, SUITE 5300, TORONTO, ON
Compare APTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APTO
Aptose Biosciences Inc
|
0.279 | 16.61M | 0 | -51.21M | -44.62M | -7.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aptose Biosciences Inc Stock (APTO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| Feb-20-20 | Initiated | Maxim Group | Buy |
| Feb-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | Piper Sandler | Overweight |
| Mar-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Nov-16-18 | Initiated | B. Riley FBR | Buy |
| Dec-13-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-17 | Resumed | ROTH Capital | Buy |
| Sep-07-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-08-17 | Initiated | Rodman & Renshaw | Neutral |
View All
Aptose Biosciences Inc Stock (APTO) Latest News
Aptose gets Nasdaq extension to regain compliance - MSN
Aptose Announces Positive Decision by Nasdaq Hearings Panel - GlobeNewswire
Aptose Biosciences Secures Critical Nasdaq Extension, Unveils $8M Offering and Cancer Drug Progress - StockTitan
Metrics That Matter About Aptose Biosciences Inc (NASDAQ: APTO) - Stocks Register
SEC Form PRE 14A filed by Aptose Biosciences Inc. - Quantisnow
Aptose Announces Publication of Preclinical Data in AACR - GlobeNewswire
Aptose's Tuspetinib Shows Breakthrough Potential in Leukemia Treatment, Clinical Data Reveals Powerful Anti-Cancer Effects - StockTitan
Aptose Biosciences: Top 10 Undervalued Healthcare Sector Stocks On TSX (APS) - Barchart
Aptose Clinical Data Featured in Poster Presentation at the - GlobeNewswire
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML - Marketscreener.com
Aptose's Tuspetinib Shows Breakthrough 60% Response Rate in AML Treatment at ASH Meeting - StockTitan
StockNews.com Initiates Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
Aptose Biosciences maintains shares target, Buy rating post-NCI deal By Investing.com - Investing.com Canada
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML - GlobeNewswire
Aptose Partners with NCI to Advance Tuspetinib Cancer Treatment in Clinical Trials - StockTitan
Aptose Biosciences Inc (APTO) Has A Gold Mine On Its Hands - Stocks Register
Aptose Biosciences CEO William Rice acquires $20,000 in shares By Investing.com - Investing.com Australia
Aptose Biosciences CEO William Rice acquires $20,000 in shares - Investing.com
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering - GlobeNewswire
Aptose Biosciences Boosts Capital with $8M Offering - TipRanks
Aptose Biosciences Completes $8M Public Offering with Insider Participation | APTO Stock News - StockTitan
Form 424B4 Aptose Biosciences Inc. - StreetInsider.com
SEC Form 424B4 filed by Aptose Biosciences Inc. - Quantisnow
Aptose sets $8 million target in stock and warrant offering By Investing.com - Investing.com Australia
Stocks In Play: Aptose Biosciences Inc. By Baystreet.ca - Investing.com Canada
Crude Oil Gains Over 1%; Ross Stores Earnings Top Views - Benzinga
Aptose sets $8 million target in stock and warrant offering - Investing.com India
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering - GlobeNewswire
Dow Jumps 300 Points; Gap Posts Upbeat Earnings - Benzinga
Aptose Biosciences Inc. - Baystreet.ca
Aptose Biosciences Announces $8 Million Public Offering - TipRanks
Aptose Biosciences Raises $8M in Public Offering with Warrant Package at $0.20 Per Share | APTO Stock News - StockTitan
Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket - Benzinga
Aptose Biosciences stock plunges to 52-week low of $0.33 By Investing.com - Investing.com Canada
Aptose Biosciences stock plunges to 52-week low of $0.33 - Investing.com India
Aptose Initiates TUSCANY Phase 1/2 Study for Newly - GlobeNewswire
Aptose Launches Phase 1/2 Trial Testing Novel AML Triplet Therapy with Tuspetinib | APTO Stock News - StockTitan
ARMISTICE CAPITAL, LLC Increases Stake in Aptose Biosciences Inc - GuruFocus.com
Aptose Biosciences Inc. (APTO) Quarterly 10-Q Report - Quartz
Aptose Biosciences Reports Q3 2024 Financial Highlights - TipRanks
Aptose Reports Results for the Third Quarter 2024 - GlobeNewswire
Aptose Biosciences Cuts Q3 Losses, Secures $10M Loan Amid Nasdaq Challenges | APTO Stock News - StockTitan
RNA-based Therapeutics Market Latest Trends Analysis Report 2024 - InsightAce Analytic
Hanmi and MEDiC ink cancer biomarker collaboration deal - Pharmaceutical Technology
Aptose Biosciences faces delisting from NASDAQ - Investing.com India
Aptose Biosciences faces delisting from NASDAQ By Investing.com - Investing.com South Africa
Analysts’ New Coverage for September 18th (AINC, AIRI, APTO, ARM, AVGO, BGNE, CAN, CARA, CHH, CLLS) - Defense World
Aptose Biosciences secures shareholder nod for warrant issuance - Investing.com
Aptose Biosciences stock hits 52-week low at $0.34 - Investing.com
Aptose Biosciences Inc Stock (APTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):